Article

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Modern Pathology (Impact Factor: 6.36). 01/2011; 24(5):653-64. DOI: 10.1038/modpathol.2010.232
Source: PubMed

ABSTRACT A new lung adenocarcinoma classification is being proposed by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS). This proposal has not yet been tested in clinical datasets to determine whether it defines prognostically significant subgroups of lung adenocarcinoma. In all, 514 patients who had pathological stage I adenocarcinoma of the lung classified according to the Union for International Cancer Control/American Joint Committee on Cancer 7th Edition, and who had undergone a lobectomy with mediastinal lymph node dissection were retrospectively reviewed. Comprehensive histological subtyping was used to estimate the percentage of each histological subtype and to identify the predominant subtype. Tumors were classified according to the proposed new IASLC/ATS/ERS adenocarcinoma classification. Statistical analyses were made including Kaplan-Meier and Cox regression analyses. There were 323 females (63%) and 191 males (37%) with a median age of 69 years (33-89 years) and 298 stage IA and 216 stage IB patients. Three overall prognostic groups were identified: low grade: adenocarcinoma in situ (n=1) and minimally invasive adenocarcinoma (n=8) had 100% 5-year disease-free survival; intermediate grade: non-mucinous lepidic predominant (n=29), papillary predominant (n=143) and acinar predominant (n=232) with 90, 83 and 84% 5-year disease-free survival, respectively; and high grade: invasive mucinous adenocarcinoma (n=13), colloid predominant (n=9), solid predominant (n=67) and micropapillary predominant (n=12), with 75, 7170 and 67%, 5-year disease-free survival, respectively (P<0.001). Among the clinicopathological factors, stage 1B versus 1A (P<0.001), male sex (P<0.008), high histological grade (P<0.001), vascular invasion (P=0.002) and necrosis (P<0.001) were poorer prognostic factors on univariate analysis. Both gross tumor size (P=0.04) and invasive tumor size adjusted by the percentage of lepidic growth (P<0.001) were significantly associated with disease-free survival with a slightly stronger association for the latter. Multivariate analysis showed the prognostic groups of the IASLC/ATS/ERS histological classification (P=0.038), male gender (P=0.007), tumor invasive size (P=0.026) and necrosis (P=0.002) were significant poor prognostic factors. In summary, the proposed IASLC/ATS/ERS classification of lung adenocarcinoma identifies histological categories with prognostic differences that may be helpful in identifying candidates for adjunctive therapy. The slightly stronger association with survival for invasive size versus gross size raises the need for further studies to determine whether this adjustment in measuring tumor size could impact TNM staging for small adenocarcinomas.

Download full-text

Full-text

Available from: Akihiko Yoshizawa, Feb 02, 2015
0 Followers
 · 
152 Views
  • Source
    • "The average number of slides from each case we reviewed in our study was 6.7 (range: 1–26). Cases were reviewed by two independent pathologists with experience in pulmonary pathology and were classified according to the recent proposed classification of adenocarcinomas by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society [22] [23] [24]. The morphologic patterns, predominant histologic subtypes (lepidic, acinar, papillary, micropapillary, cribriform, and solid), presence of lymphovascular invasion, pleural invasion, and other clinical data were recorded. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapies targeting EGFR are effective in treating tumors that harbor molecular alterations; however, there is heterogeneity in long-term response to these therapies. We retrospectively analyzed protein expression of EGFR, Stat3, phospho-Akt, and phospho-Erk1/2 by immunohistochemistry in a series of resected cases from a single institution, correlated with clinicopathological variables. There were 96 patients, with the majority of cases being of low stage tumors (17 pT1a, 23 pT1b, 30 pT2a, and 18 pT2b). Histologic subtypes were 45 acinar predominant, 2 cribriform, 25 solid, 7 papillary, 11 lepidic, and 4 mucinous tumors. The EGFR score was higher in tumors with vascular invasion (í µí±ƒ = 0.013), in solid and cribriform acinar histology, and in high stage tumors (í µí±ƒ = 0.006 and í µí±ƒ = 0.01). EGFR was more likely overexpressed in solid compared to lepidic tumors (í µí±ƒ = 0.02). Acinar tumors had the highest rate of ERK1/2 positivity (19%). There was a strong correlation among positivity for ERCC1 and other markers, including STAT3 (í µí±ƒ = 0.003), Akt (í µí±ƒ = 0.02), and ERK1/ERK2 (í µí±ƒ = 0.0005). Expression of molecules downstream to EGFR varied from 12% to 31% of tumors; however, the expression did not directly correlate to EGFR expression, which may suggest activation of the cascades through different pathways. The correlation of protein expression and the new lung adenocarcinoma classification may help in the understanding of activated pathways of each tumor type, which may act in the oncogenesis and drug resistance of these tumors.
    Analytical cellular pathology: the journal of the European Society for Analytical Cellular Pathology 12/2014; 2014. DOI:10.1155/2014/352925
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: El carcinoma de pulmón es el cáncer que produce mayor mortalidad en el mundo. A pesar de los progresos en las estrategias de tratamiento y en algunos métodos de detec-ción, la mortalidad global se ha modificado poco. Los avances en biología molecular nos han permitido enten-der mejor el origen, el desarrollo y la evolución del cáncer de pulmón. Nuevos conocimientos en patología, radiología, oncología y cirugía han marcado la importancia del enfoque multidisciplinario del paciente con cáncer de pulmón y, entre otras cosas, han originado la necesidad de cambios en la clasificación del carcinoma pulmonar, así como de mayor especificidad en el momento del diagnóstico dado el surgimiento de terapéuticas diferentes de acuerdo con el tipo histológico y las características moleculares del tumor. CLASIFICACIÓN ACTUAL DE CARCINOMA DE PULMÓN La clasificación de tipos histológicos de los tumores de pulmón en vigencia es la publicada por la Organización Mundial de la Salud (OMS) en el año 2004. 1 Los mayores cambios de los últimos años se han produci-do fundamentalmente en relación con el adenocarcinoma (ADC). Las razones son varias: 1) el ADC creció proporcio-nalmente en frecuencia sobre los otros tipos de carcinoma y constituye hoy el carcinoma pulmonar más frecuente; 2) algunos estudios de lesiones pequeñas de ADC mostraron diferencias significativas en el pronóstico en diferentes ADC; 3) se efectuaron múltiples estudios con tomografía de alta resolución (TCAR) de pacientes con cáncer de pul-món; estos revelaron características de las imágenes que permitieron hacer una correlación estrecha con diferentes tipos de ADC, y además con el pronóstico; 4) estudios de biología molecular mostraron diferencias significativas entre distintos tipos de adenocarcinomas.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung adenocarcinoma is a heterogeneous group of tumors with a highly variable prognosis, not well predicted by the current pathologic classification system. The 2004 World Health Organization classification results in virtually all tumors encountered in clinical practice being allocated to the adenocarcinoma of mixed subtype category. A new classification developed by an international multidisciplinary expert panel sponsored by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society, is based on histomorphologic subtype and has recently been validated in a North American series of 514 stage I lung adenocarcinomas. We investigated the relationship between the new classification and patient survival in a series of Australian patients with stages I, II, and III lung adenocarcinoma. We identified 210 patients from a surgical database who underwent resection of lung adenocarcinoma from 1996 to 2009. Two pathologists, blinded to patient outcome, independently performed histopathologic subtyping according to the new classification. Kaplan-Meier curves were used to calculate 5-year survival for each separate histopathologic subtype/variant. Univariate and multivariate analyses were undertaken to control for validated prognostic factors. We confirmed that the new subtypes of adenocarcinoma in situ, minimally invasive adenocarcinoma and lepidic-predominant adenocarcinoma had a 5-year survival approaching 100%, whereas micropapillary-predominant and solid with mucin-predominant adenocarcinomas were associated with particularly poor survival. Papillary-predominant and acinar-predominant adenocarcinomas had an intermediate prognosis. This effect persisted after controlling for stage. Classification of lung adenocarcinoma according to the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification correlated with 5-year survival. These relationships persisted after controlling for known prognostic patient and tumor characteristics. The new classification has advantages not only for individual patient care but also for better selection and stratification for clinical trials and molecular studies.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 06/2011; 6(9):1496-504. DOI:10.1097/JTO.0b013e318221f701 · 5.80 Impact Factor